Chinese Study Finds GLP-1 Drug Eases Depression in Mice via 1 Gut Bacterium
Updated
Updated · Courthouse News Service · Jun 10
Chinese Study Finds GLP-1 Drug Eases Depression in Mice via 1 Gut Bacterium
3 articles · Updated · Courthouse News Service · Jun 10
Summary
Liraglutide reduced depression- and anxiety-like behavior in stressed mice, with Chinese researchers tying the effect to gut-microbiome changes rather than direct action in the brain.
Lactobacillus delbrueckii rose after treatment and appeared to drive production of a stress-calming compound; when gut bacteria were wiped out with antibiotics or absent in germ-free mice, the antidepressant effect vanished.
The team said liraglutide accumulated mainly in the intestine and still worked in mice lacking the drug’s usual receptors, challenging the prevailing view that GLP-1 agonists act through brain GLP-1 receptors.
The findings point to potential probiotic or metabolite-based depression treatments for people with or without metabolic disease, in a field where prior studies on GLP-1 drugs and mood had produced conflicting results.
Are weight-loss drugs secretly mood regulators that work by rebalancing our gut microbiome?
Could a targeted 'psychobiotic' pill become a mainstream treatment for depression, bypassing the brain entirely?
Breakthrough 2026: GLP-1 Diabetes Drugs Treat Depression Through Gut Bacteria, Not Brain
Overview
A recent Chinese study published in June 2026 revealed that GLP-1 drugs, like liraglutide, can reduce depressive behaviors by acting through the gut microbiome rather than directly on the brain. These drugs accumulate in the intestine, encouraging the growth of beneficial bacteria such as Lactobacillus delbrueckii. This bacterium helps produce diacylglycerol, which is then used to create endocannabinoids that influence brain function and mood. This discovery highlights a new gut-brain pathway for treating depression and suggests that targeting the gut microbiome could offer innovative options for mental health therapy.